Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion type Assertion NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_head.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion description "[We assessed the safety and activity of the oral BRAF inhibitor vemurafenib in patients with hairy-cell leukemia that had relapsed after treatment with a purine analogue or who had disease that was refractory to purine analogues.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_provenance.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion evidence source_evidence_literature NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_provenance.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion SIO_000772 26352686 NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_provenance.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion wasDerivedFrom befree-2016 NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_provenance.
- NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_assertion wasGeneratedBy ECO_0000203 NP1293888.RAJ0mg4m_QYe8yaeOSnjmtWwibCxMe1sNF_eF9-s6NXAA130_provenance.